180 Wealth Advisors LLC Makes New $255,000 Investment in DexCom, Inc. (NASDAQ:DXCM)

180 Wealth Advisors LLC bought a new stake in DexCom, Inc. (NASDAQ:DXCM) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 3,280 shares of the medical device company’s stock, valued at approximately $255,000.

Other large investors also recently made changes to their positions in the company. Blue Whale Capital LLP grew its position in shares of DexCom by 91.9% during the 3rd quarter. Blue Whale Capital LLP now owns 236,000 shares of the medical device company’s stock worth $15,821,000 after purchasing an additional 113,000 shares in the last quarter. Taylor Frigon Capital Management LLC grew its position in DexCom by 51.6% during the third quarter. Taylor Frigon Capital Management LLC now owns 32,554 shares of the medical device company’s stock worth $2,182,000 after buying an additional 11,075 shares in the last quarter. Brooktree Capital Management bought a new position in DexCom during the 3rd quarter worth $683,000. National Pension Service raised its holdings in DexCom by 4.1% in the 3rd quarter. National Pension Service now owns 949,743 shares of the medical device company’s stock valued at $63,671,000 after acquiring an additional 37,363 shares in the last quarter. Finally, Intact Investment Management Inc. acquired a new stake in shares of DexCom during the 3rd quarter worth $650,000. Institutional investors own 97.75% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Sadie Stern sold 4,259 shares of the company’s stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total transaction of $318,275.07. Following the transaction, the executive vice president now owns 71,192 shares in the company, valued at approximately $5,320,178.16. This represents a 5.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.30% of the company’s stock.

DexCom Stock Up 1.6 %

Shares of DexCom stock opened at $80.40 on Thursday. The stock’s 50-day moving average is $77.57 and its 200 day moving average is $78.37. DexCom, Inc. has a one year low of $62.34 and a one year high of $142.00. The firm has a market cap of $31.40 billion, a price-to-earnings ratio of 48.14, a PEG ratio of 2.36 and a beta of 1.12. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. Wells Fargo & Company boosted their price target on DexCom from $90.00 to $94.00 and gave the company an “overweight” rating in a research note on Wednesday, December 11th. Citigroup boosted their target price on shares of DexCom from $85.00 to $91.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. JPMorgan Chase & Co. increased their price target on shares of DexCom from $75.00 to $85.00 and gave the stock a “neutral” rating in a research report on Friday, October 25th. Leerink Partners lowered their price objective on shares of DexCom from $90.00 to $87.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. Finally, Raymond James reduced their target price on DexCom from $115.00 to $99.00 and set a “strong-buy” rating on the stock in a report on Friday, October 25th. Seven investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $98.00.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.